Advanced bladder cancer: New agents and new approaches. A review
- 1 January 2013
- journal article
- review article
- Published by Elsevier BV in Urologic Oncology
- Vol. 31 (1), 9-16
- https://doi.org/10.1016/j.urolonc.2010.03.022
Abstract
No abstract availableKeywords
This publication has 53 references indexed in Scilit:
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Phase 2 trial of epothilone B analog BMS‐247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800)Cancer, 2007
- Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinomaInvestigational New Drugs, 2006
- Schedule Dependent Efficacy of Gefitinib and Docetaxel for Bladder CancerJournal of Urology, 2006
- Novel Approach of Human Epidermal Growth Factor Receptor 2 Detection in Noninvasive and Invasive Transitional Cell Carcinoma of the BladderJournal of Urology, 2006
- Multicentre EORTC study 16997: Feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancersEuropean Journal of Cancer, 2005
- A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinomaCancer, 2005
- Farnesyltransferase inhibitor SCH‐66336 downregulates secretion of matrix proteinases and inhibits carcinoma cell migrationInternational Journal of Cancer, 2005
- M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder: The french federation of cancer centers experienceEuropean Journal of Cancer and Clinical Oncology, 1991
- Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumorsCancer, 1991